
Lilly’s Oral GLP-1 Candidate Demonstrates 27-Pound Average Weight Loss in Phase III Trial
Eli Lilly and Company is reporting clinically meaningful weight loss data from a Phase III trial (ATTAIN-1) of orforglipron, its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist (1). In the study of more than 3000 adults with obesity, …